

# NOW ENROLLING IN ADJUVANT MELANOMA



PHASE 3 (NCT04410445)

## PIVOT-12: Bempegaldesleukin with nivolumab for the adjuvant treatment of melanoma at high risk of recurrence

A Phase 3, randomized, open-label study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy for the adjuvant treatment of patients with completely resected melanoma at high risk of recurrence<sup>1</sup>

**ENROLL NOW**

Scan here to find out more about this clinical study at [ClinicalTrials.gov](https://clinicaltrials.gov)



### POPULATION

- Age ≥12 years
- Resected Stage IIIa–IV melanoma with no evidence of disease

N≈950

R  
1:1<sup>a</sup>

BEMPEG + NIVO

NIVO

### PRIMARY ENDPOINT

- Recurrence-free survival<sup>b</sup>

### SECONDARY ENDPOINTS

- Overall survival
- Distant metastasis-free survival
- Safety and tolerability
- Quality of life

Bempegaldesleukin is an investigational first-in-class CD122-preferential IL-2–pathway agonist<sup>2</sup>  
Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody<sup>3</sup>

<sup>a</sup>Randomization is stratified by PD-L1 status and stage (American Joint Committee on Cancer 8th edition).

<sup>b</sup>Assessed by blinded independent central review.

BEMPEG, bempegaldesleukin (NKTR-214); IL-2, interleukin-2; NIVO, nivolumab.

1. [ClinicalTrials.gov](https://clinicaltrials.gov). NCT04410445. <https://clinicaltrials.gov/ct2/show/NCT04410445>. Accessed September 3, 2020. 2. Charych DH, et al. *Clin Cancer Res* 2016;22:680–690.

3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: June 2020).

# ACTIVE CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB


NEKTAR

 Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverage two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

**FIND OUT MORE**

Scan here to discover more about BEMPEG at Nektar.com



BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab.

**FOR EDUCATIONAL PURPOSES ONLY.**

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2020. All rights reserved.